| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3c16b0bbc3bd05d9455b6bb499f1845 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66 |
| filingDate |
2012-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07d7c79d1864be861214e9d5ca379c04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4dc7bc8ead5caaad97d7a6679d71abc7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe2d5c7fdbdd2f7d1d63c5e4bff5edc7 |
| publicationDate |
2013-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-103458896-A |
| titleOfInvention |
methods used to treat cancer |
| abstract |
TH-302 or other hypoxia-activated prodrugs are administered in combination with pharmacological agents that downregulate or inhibit homology-directed repair (HDR) for the treatment of cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020007106-A1 |
| priorityDate |
2011-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |